Dalbavancin — Dose Evidence | Peptides Community

Reference only — not a dosing recommendation.

Approved regimen

Approved labeled regimen

Product-, indication-, and jurisdiction-specific — see the monograph

Adults (two-dose): 1,000 mg IV followed 1 wk later by 500 mg IV. Single-dose: 1,500 mg IV ×1. Pediatric (3 mo to <18 y): weight-based. Infuse over 30 min. Renal impairment (CrCl <30 mL/min): two-dose regimen — 750 mg/375 mg; single dose — 1,125 mg.

Not established

What is not established

Use beyond ABSSSI (e.g., osteomyelitis, endocarditis — off-label studied but not approved).
Use in pregnancy: limited human data.
Pediatric patients <3 months: very limited data.

Dalbavancin — monograph dose and administration evidence